Why Online Pharmacology CME for PAs is the Smartest Way to Spend Your 2026 Stipend

Pharmacology CME Review Package

• Price: $399.99 (Base) – Up to $1,999.00 (with Gift Card Add-On)
• Deliverables: 12 Hours of AAPA Category 1 Pharmacology Credit
• Access: 30 Months

PANRE Review Course

• Price: $399.99 (Base) – Up to $2,500.00 (with Gift Card Add-On)
• Deliverables: 100 Hours of AAPA Category 1 Credit
• Access: 30 Months (Base) or 12 Months (with Gift Card)

The June 30th deadline is approaching rapidly. For many physician assistants, this date marks the end of the fiscal year and the expiration of annual CME stipends. If you do not utilize your professional development funds by this cutoff, the money typically reverts to your employer. Investing in high-quality pharmacology CME is a strategic method to satisfy state licensing requirements while ensuring your stipend is fully utilized.

The Necessity of Targeted Pharmacology CME

Pharmacology is a cornerstone of clinical practice for physician assistants across all specialties. However, keeping pace with evolving drug therapies, interactions, and prescribing guidelines is a continuous challenge. Most state medical boards and licensing bodies require a specific number of pharmacology-specific credits to maintain prescriptive authority.

Our Pharmacology CME Review Package provides 12 hours of AAPA Category 1 credit focused entirely on pharmacological management. This content was developed by physician assistants for physician assistants, ensuring the material is relevant to your daily clinical decision-making. Whether you are managing complex hypertension in family medicine or navigating anticoagulation in the hospitalist setting, these credits serve a dual purpose: fulfilling regulatory mandates and sharpening your clinical expertise.

The June 30 "Use It or Lose It" Deadline

The "use it or lose it" nature of employer stipends creates a seasonal rush for CME. Waiting until the final week of June to select a course often leads to rushed decisions or administrative delays that could jeopardize your reimbursement. By securing your course now, you ensure that your CME with Gift Card purchase is processed well before the fiscal year-end.

Many hospital systems require the purchase date to fall within the current fiscal cycle. Our system is optimized to provide immediate access and documentation, allowing you to submit your materials to your administration efficiently.

Maximize Your Stipend: The Gift Card Add-On

If your employer provides a generous stipend (e.g., $2,500), but the course you need only costs $400, you are essentially leaving $2,100 on the table. We offer a solution that allows you to maximize your professional budget.

By choosing our CME with Amazon or Apple Gift Card add-ons, you can add between $100 and $1,500 to your purchase. This allows you to enrich your education by purchasing medical textbooks, upgraded hardware (like a new iPad for clinical use), or other supplies necessary for your practice. This is a pragmatic approach to ensuring every dollar of your 2026 stipend is utilized to its full potential.

---

Clinical Pharmacology Assessment

Test your knowledge with these clinical vignettes. These scenarios reflect the types of pharmacological management decisions encountered in daily practice and on the PANRE.

Question 1

Your patient is a 64-year-old male with a history of chronic heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD) Stage 3. His current medications include lisinopril, carvedilol, and furosemide. During a routine follow-up, his potassium level is 4.2 mEq/L and his blood pressure is 138/84 mmHg. You decide to initiate an aldosterone antagonist. Which of the following is the most appropriate next step in monitoring this patient?

A. Check serum creatinine and potassium levels within 1 week of initiation.
B. Monitor for clinical signs of hypercalcemia in 2 weeks.
C. Assess for ototoxicity every 3 months.
D. Recheck liver function tests (LFTs) in 30 days.

Explanation:
A is the correct answer. When initiating an aldosterone antagonist (such as spironolactone or eplerenone), particularly in patients already receiving an ACE inhibitor and those with baseline CKD, the risk of hyperkalemia and acute kidney injury is significant. Monitoring serum creatinine and potassium within 3 to 7 days is mandatory.

• Choice B is incorrect because aldosterone antagonists are associated with hyperkalemia, not hypercalcemia.
• Choice C is incorrect as ototoxicity is a potential side effect of loop diuretics (like high-dose furosemide), not aldosterone antagonists.
• Choice D is incorrect because these medications are primarily cleared renally; LFT monitoring is not the primary safety concern.

Question 2

Your patient is a 52-year-old female presenting for management of newly diagnosed Type 2 Diabetes Mellitus. Her HbA1c is 8.4%. She has a documented history of atherosclerotic cardiovascular disease (ASCVD) following a myocardial infarction two years ago. In addition to lifestyle modifications and metformin, which class of medication is prioritized according to current guidelines for this patient?

A. GLP-1 receptor agonist (GLP-1 RA).
B. Sulfonylurea.
C. DPP-4 inhibitor.
D. Thiazolidinedione (TZD).

Explanation:
A is the correct answer. For patients with Type 2 Diabetes and established ASCVD, the use of a GLP-1 receptor agonist or an SGLP2 inhibitor with proven cardiovascular benefit is recommended regardless of the baseline HbA1c or metformin use.

• Choice B is incorrect because sulfonylureas carry a high risk of hypoglycemia and have no cardiovascular benefits.
• Choice C is incorrect as DPP-4 inhibitors are considered neutral regarding cardiovascular outcomes and are less potent than GLP-1 RAs.
• Choice D is incorrect because TZDs are associated with weight gain and potential exacerbation of heart failure.

---

Scaling Up: The 100-Hour PANRE Review Course

While the pharmacology package is ideal for focused credit needs, many physician assistants require a more robust solution for their recertification cycle. The PANRE Review Course provides 100 hours of AAPA Category 1 credit.

This course is comprehensive, covering the NCCPA Blueprint including Cardiology, Pulmonology, Gastroenterology, and more. If you are preparing for the PANRE or the PANRE-LA, this course provides the structured review necessary to succeed. Like the pharmacology package, the PANRE Review is eligible for gift card add-ons up to $1,500, making it the most efficient way to use a large CME stipend before June 30th.

---

PANRE Comprehensive Assessment

Question 3

Your patient is a 28-year-old female complaining of a "racing heart" and unintentional weight loss. On physical exam, her HR is 112 bpm, and she has a fine tremor in her hands. Laboratory results show a TSH of <0.01 uIU/mL and an elevated Free T4. You suspect Graves' disease. Which pharmacological agent should be initiated for rapid symptom control of her palpitations and tremor?

A. Propranolol.
B. Methimazole.
C. Propylthiouracil (PTU).
D. Radioactive Iodine.

Explanation:
A is the correct answer. Beta-blockers, specifically propranolol, are the first-line treatment for the symptomatic management of thyrotoxicosis to control tachycardia, palpitations, and tremors while awaiting the effects of antithyroid medications.

• Choice B and C are incorrect because while they treat the underlying hyperthyroidism by inhibiting thyroid hormone synthesis, they do not provide immediate relief of adrenergic symptoms.
• Choice D is incorrect because it is a definitive treatment for hyperthyroidism and may initially worsen symptoms due to the release of stored thyroid hormone.

Question 4

Your patient is a 45-year-old male presenting to the emergency department with acute onset of severe pain, redness, and swelling in his left first metatarsophalangeal (MTP) joint. Joint aspiration reveals negatively birefringent, needle-shaped crystals. He has a history of stage 3 CKD. Which of the following is the preferred first-line pharmacological treatment for this acute flare?

A. Prednisone.
B. Indomethacin.
C. Allopurinol.
D. Colchicine at high doses (e.g., 1.2 mg every hour).

Explanation:
A is the correct answer. In patients with acute gout and significant renal impairment (CKD Stage 3 or higher), corticosteroids like prednisone are preferred over NSAIDs (like indomethacin) or colchicine to avoid the risk of acute renal failure or toxicity.

• Choice B is incorrect because NSAIDs are generally contraindicated or used with extreme caution in patients with CKD.
• Choice C is incorrect because allopurinol is a urate-lowering therapy used for chronic management and can potentially worsen an acute flare if initiated during the attack.
• Choice D is incorrect because high-dose colchicine is no longer recommended due to toxicity; additionally, colchicine requires significant dose adjustments in CKD.

---

Conclusion

Maximizing your professional benefits requires proactive planning. By selecting the Pharmacology CME Review Package or the 100-hour PANRE Review Course, you ensure your 2026 stipend is used effectively before the June 30th deadline. These courses provide high-yield clinical content and the flexibility of gift card add-ons to further support your educational needs.

Secure your credits today and enter the new fiscal year with your certification requirements met and your professional tools updated.